R-30490
Systematic (IUPAC) name | |
---|---|
N-[4-(methoxymethyl)-1-(2-phenylethyl)-4-piperidinyl]-N-phenyl-propanamide | |
Clinical data | |
Pregnancy category |
|
Pharmacokinetic data | |
Bioavailability | ? |
Protein binding | ? |
Metabolism | ? |
Excretion | ? |
Identifiers | |
CAS Number | 60618-49-7 |
PubChem | CID 124716 |
ChemSpider | 111042 |
ChEMBL | CHEMBL609147 |
Chemical data | |
Formula | C24H32N2O2 |
Molar mass | 380.522 g/mol |
| |
| |
(what is this?) (verify) |
R-30490 is an opioid analgesic related to the highly potent animal tranquilizer carfentanil, and with only slightly lower potency. It was first synthesised by a team of chemists at Janssen Pharmaceutica led by Paul Janssen, who were investigating the structure-activity relationships of the fentanyl family of drugs. R-30490 was found to be the most selective agonist for the mu opioid receptor out of all the fentanyl analogues tested, but it has never been introduced for medical use in humans, although the closely related drug sufentanil is widely used for analgesia and anesthesia during major surgery.[1][2][3][4]
Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear.[5]
References
- ↑ Cometta-Morini, C.; Maguire, P. A.; Loew, G. H. (1992). "Molecular determinants of mu receptor recognition for the fentanyl class of compounds". Molecular Pharmacology 41 (1): 185–196. PMID 1310142.
- ↑ Maguire, P.; Tsai, N.; Kamal, J.; Cometta-Morini, C.; Upton, C.; Loew, G. (1992). "Pharmacological profiles of fentanyl analogs at μ, δ and κ opiate receptors". European Journal of Pharmacology 213 (2): 219–225. doi:10.1016/0014-2999(92)90685-W. PMID 1355735.
- ↑ Meert, T. F. (1996). "Pharmacotherapy of opioids: Present and future developments". Pharmacy World & Science 18 (1): 1–15. doi:10.1007/BF00449683. PMID 8861825.
- ↑ Subramanian, G.; Paterlini, M. G.; Portoghese, P. S.; Ferguson, D. M. (2000). "Molecular Docking Reveals a Novel Binding Site Model for Fentanyl at the μ-Opioid Receptor". Journal of Medicinal Chemistry 43 (3): 381–391. doi:10.1021/jm9903702. PMID 10669565.
- ↑ Jane Mounteney, Isabelle Giraudon, Gleb Denissov, Paul Griffiths (July 2015). "Fentanyls: Are we missing the signs? Highly potent and on the rise in Europe.". The international journal of drug policy. 26 (7): 626–631. doi:10.1016/j.drugpo.2015.04.003. PMID 25976511.